GB0202015D0 - Piperazine Derivatives - Google Patents

Piperazine Derivatives

Info

Publication number
GB0202015D0
GB0202015D0 GBGB0202015.4A GB0202015A GB0202015D0 GB 0202015 D0 GB0202015 D0 GB 0202015D0 GB 0202015 A GB0202015 A GB 0202015A GB 0202015 D0 GB0202015 D0 GB 0202015D0
Authority
GB
United Kingdom
Prior art keywords
piperazine derivatives
piperazine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0202015.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Ligand UK Research Ltd
Original Assignee
F Hoffmann La Roche AG
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Vernalis Research Ltd filed Critical F Hoffmann La Roche AG
Priority to GBGB0202015.4A priority Critical patent/GB0202015D0/en
Publication of GB0202015D0 publication Critical patent/GB0202015D0/en
Priority to DE60303791T priority patent/DE60303791T2/de
Priority to YU65704A priority patent/RS65704A/sr
Priority to DK03702462T priority patent/DK1472255T3/da
Priority to AT03702462T priority patent/ATE318817T1/de
Priority to BR0307291-6A priority patent/BR0307291A/pt
Priority to CNB03802943XA priority patent/CN1290847C/zh
Priority to ES03702462T priority patent/ES2259757T3/es
Priority to AU2003205622A priority patent/AU2003205622B2/en
Priority to MXPA04007147A priority patent/MXPA04007147A/es
Priority to JP2003564046A priority patent/JP4213042B2/ja
Priority to EA200400881A priority patent/EA200400881A1/ru
Priority to IL16272703A priority patent/IL162727A0/xx
Priority to PCT/EP2003/000459 priority patent/WO2003064423A1/en
Priority to CA002472954A priority patent/CA2472954C/en
Priority to PL03371922A priority patent/PL371922A1/xx
Priority to HR20040653A priority patent/HRP20040653A2/hr
Priority to KR1020047011619A priority patent/KR100644004B1/ko
Priority to SI200330231T priority patent/SI1472255T1/sl
Priority to EP03702462A priority patent/EP1472255B1/en
Priority to PT03702462T priority patent/PT1472255E/pt
Priority to US10/350,616 priority patent/US7098337B2/en
Priority to PE2003000073A priority patent/PE20030847A1/es
Priority to ARP030100229A priority patent/AR038237A1/es
Priority to GT200300015A priority patent/GT200300015A/es
Priority to UY27627A priority patent/UY27627A1/es
Priority to PA20038564001A priority patent/PA8564001A1/es
Priority to TW092101825A priority patent/TW200307683A/zh
Priority to MA27756A priority patent/MA27097A1/fr
Priority to ZA200405458A priority patent/ZA200405458B/en
Priority to TNP2004000136A priority patent/TNSN04136A1/en
Priority to EC2004005208A priority patent/ECSP045208A/es
Priority to NO20043547A priority patent/NO20043547L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
GBGB0202015.4A 2002-01-29 2002-01-29 Piperazine Derivatives Ceased GB0202015D0 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
GBGB0202015.4A GB0202015D0 (en) 2002-01-29 2002-01-29 Piperazine Derivatives
PT03702462T PT1472255E (pt) 2002-01-29 2003-01-17 Aza-arilpiperazinas
HR20040653A HRP20040653A2 (hr) 2002-01-29 2003-01-17 Aza-arylpiperazines
KR1020047011619A KR100644004B1 (ko) 2002-01-29 2003-01-17 아자-아릴피페라진
DK03702462T DK1472255T3 (da) 2002-01-29 2003-01-17 Aza-arylpiperaziner
AT03702462T ATE318817T1 (de) 2002-01-29 2003-01-17 Aza-arylpiperazine
BR0307291-6A BR0307291A (pt) 2002-01-29 2003-01-17 Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; método para o tratamento e profilaxia de distúrbios diversos e de obesidade em um humano
CNB03802943XA CN1290847C (zh) 2002-01-29 2003-01-17 氮杂－芳基哌嗪类化合物
ES03702462T ES2259757T3 (es) 2002-01-29 2003-01-17 Aza-arilpiperazinas.
AU2003205622A AU2003205622B2 (en) 2002-01-29 2003-01-17 Aza-arylpiperazines
MXPA04007147A MXPA04007147A (es) 2002-01-29 2003-01-17 Aza-arilpiperazinas.
JP2003564046A JP4213042B2 (ja) 2002-01-29 2003-01-17 アザ−アリールピペラジン
EA200400881A EA200400881A1 (ru) 2002-01-29 2003-01-17 Азаарилпиперазины
IL16272703A IL162727A0 (en) 2002-01-29 2003-01-17 Aza-arylpiperazines
PCT/EP2003/000459 WO2003064423A1 (en) 2002-01-29 2003-01-17 Aza-arylpiperazines
CA002472954A CA2472954C (en) 2002-01-29 2003-01-17 Aza-arylpiperazines
PL03371922A PL371922A1 (en) 2002-01-29 2003-01-17 Aza-arylpiperazines
DE60303791T DE60303791T2 (de) 2002-01-29 2003-01-17 Aza-arylpiperazine
EP03702462A EP1472255B1 (en) 2002-01-29 2003-01-17 Aza-arylpiperazines
YU65704A RS65704A (sr) 2002-01-29 2003-01-17 Aza-arilpiperazini
SI200330231T SI1472255T1 (sl) 2002-01-29 2003-01-17 Aza-arilpiperazini
US10/350,616 US7098337B2 (en) 2002-01-29 2003-01-24 1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives
PE2003000073A PE20030847A1 (es) 2002-01-29 2003-01-24 Aza-arilpiperazinas como ligandos del receptor 5ht2
ARP030100229A AR038237A1 (es) 2002-01-29 2003-01-27 Aza-arilpiperazinas
GT200300015A GT200300015A (es) 2002-01-29 2003-01-27 Aza-arilpiperazinas
UY27627A UY27627A1 (es) 2002-01-29 2003-01-28 Aza - arilpiperazinas
PA20038564001A PA8564001A1 (es) 2002-01-29 2003-01-28 Aza-arilpiperazinas
TW092101825A TW200307683A (en) 2002-01-29 2003-01-28 Aza-arylpiperazines
MA27756A MA27097A1 (fr) 2002-01-29 2004-06-30 Aza-arylpiperazines
ZA200405458A ZA200405458B (en) 2002-01-29 2004-07-08 Aza-arylpiperazines.
TNP2004000136A TNSN04136A1 (en) 2002-01-29 2004-07-22 Aza-arylpiperazines
EC2004005208A ECSP045208A (es) 2002-01-29 2004-07-27 Aza-arilpiperazinas
NO20043547A NO20043547L (no) 2002-01-29 2004-08-25 Aza-arylpiperaziner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0202015.4A GB0202015D0 (en) 2002-01-29 2002-01-29 Piperazine Derivatives

Publications (1)

Publication Number Publication Date
GB0202015D0 true GB0202015D0 (en) 2002-03-13

Family

ID=9929954

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0202015.4A Ceased GB0202015D0 (en) 2002-01-29 2002-01-29 Piperazine Derivatives

Country Status (33)

Country Link
US (1) US7098337B2 (enExample)
EP (1) EP1472255B1 (enExample)
JP (1) JP4213042B2 (enExample)
KR (1) KR100644004B1 (enExample)
CN (1) CN1290847C (enExample)
AR (1) AR038237A1 (enExample)
AT (1) ATE318817T1 (enExample)
AU (1) AU2003205622B2 (enExample)
BR (1) BR0307291A (enExample)
CA (1) CA2472954C (enExample)
DE (1) DE60303791T2 (enExample)
DK (1) DK1472255T3 (enExample)
EA (1) EA200400881A1 (enExample)
EC (1) ECSP045208A (enExample)
ES (1) ES2259757T3 (enExample)
GB (1) GB0202015D0 (enExample)
GT (1) GT200300015A (enExample)
HR (1) HRP20040653A2 (enExample)
IL (1) IL162727A0 (enExample)
MA (1) MA27097A1 (enExample)
MX (1) MXPA04007147A (enExample)
NO (1) NO20043547L (enExample)
PA (1) PA8564001A1 (enExample)
PE (1) PE20030847A1 (enExample)
PL (1) PL371922A1 (enExample)
PT (1) PT1472255E (enExample)
RS (1) RS65704A (enExample)
SI (1) SI1472255T1 (enExample)
TN (1) TNSN04136A1 (enExample)
TW (1) TW200307683A (enExample)
UY (1) UY27627A1 (enExample)
WO (1) WO2003064423A1 (enExample)
ZA (1) ZA200405458B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
EP1636224B1 (en) * 2003-05-21 2010-07-14 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
CN1867332A (zh) * 2003-10-24 2006-11-22 索尔瓦药物有限公司 包含选择性cb1－拮抗剂和脂肪酶抑制剂的肥胖症的联合治疗
AR046132A1 (es) * 2003-10-24 2005-11-23 Solvay Pharm Gmbh Composicin farmaceutica que contiene al menos un compuesto con actividad de receptor de cb1, o un profarmaco , tautomero o sal del mismo, como componente activo adecuado para el tratamiento y/o profilaxis de enfermedades relacionadas con el receptor cb1 en pacientes juveniles y/o para el tratamiento
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
RU2007119315A (ru) 2004-10-25 2008-11-27 Зольвай Фармасьютиклз Гмбх (De) Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
CA2609634C (en) * 2005-05-03 2011-02-01 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-ht2 ligands
WO2006125179A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
US7622466B2 (en) * 2005-11-18 2009-11-24 Hoffman-La Roche Inc. Azaindole-2-carboxamide derivatives
ES2333672T3 (es) 2005-12-09 2010-02-25 F. Hoffmann-La Roche Ag Derivados de amida triciclica para tratamiento de obesidad.
BRPI0619985A2 (pt) 2005-12-16 2011-10-25 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CA2870019C (en) * 2012-04-26 2020-08-18 Francis Xavier Tavares Synthesis of lactams
CA2880682A1 (en) * 2012-08-06 2014-02-13 F. Hoffmann-La Roche Ag Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CA3033142A1 (en) * 2016-08-19 2018-02-22 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CA2340056C (en) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
PT1105123E (pt) 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
FR2799757B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
GT200300015A (es) 2003-09-12
TNSN04136A1 (en) 2007-03-12
WO2003064423A1 (en) 2003-08-07
DE60303791D1 (en) 2006-04-27
CA2472954A1 (en) 2003-08-07
BR0307291A (pt) 2004-12-07
KR20040077885A (ko) 2004-09-07
CA2472954C (en) 2009-04-28
PT1472255E (pt) 2006-06-30
EP1472255B1 (en) 2006-03-01
DE60303791T2 (de) 2006-11-02
ZA200405458B (en) 2006-02-22
ECSP045208A (es) 2004-09-28
AR038237A1 (es) 2005-01-05
AU2003205622B2 (en) 2006-10-19
ES2259757T3 (es) 2006-10-16
CN1625558A (zh) 2005-06-08
PL371922A1 (en) 2005-07-11
PE20030847A1 (es) 2003-10-21
JP4213042B2 (ja) 2009-01-21
US7098337B2 (en) 2006-08-29
EA200400881A1 (ru) 2005-02-24
PA8564001A1 (es) 2003-09-05
KR100644004B1 (ko) 2006-11-10
HRP20040653A2 (hr) 2005-06-30
EP1472255A1 (en) 2004-11-03
CN1290847C (zh) 2006-12-20
TW200307683A (en) 2003-12-16
ATE318817T1 (de) 2006-03-15
JP2005521671A (ja) 2005-07-21
US20030207888A1 (en) 2003-11-06
RS65704A (sr) 2006-10-27
MXPA04007147A (es) 2004-10-29
SI1472255T1 (sl) 2006-06-30
DK1472255T3 (da) 2006-07-10
NO20043547L (no) 2004-08-25
IL162727A0 (en) 2005-11-20
UY27627A1 (es) 2003-07-31
MA27097A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
AP1850A (en) Spiroindolineplperidine derivatives
EG24050A (en) Heterocylocarboxamide derivatives
PL374718A1 (en) Azolidinone-vinyl fused-benzene derivatives
IL166121A0 (en) Indole-3-sulphur derivatives
EP1522540A4 (en) AZAARENE DERIVATIVES
PL376475A1 (en) N-substituted-2-oxodihydropyridine derivatives
PL375220A1 (en) Piperidine derivatives
PL369076A1 (en) Piperazine derivative
ZA200500471B (en) N-biarylmethyl aminocycloalkanecarboxamide derivatives
TWI368482B (en) New 2-pyridinylethylbenzamide derivatives
GB0315870D0 (en) Heterocyclic derivatives
GB0106177D0 (en) Piperazine derivatives
IL162765A0 (en) Piperidine derivatives
AU2003222659A8 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
GB0423856D0 (en) Amide derivatives
EP1531854A4 (en) O-DERIVATED NOCATHIACIN DERIVATIVES
GB0219687D0 (en) Benzyl morpholine derivatives
GB0213488D0 (en) 2-Naphthamide derivatives
GB0326148D0 (en) Morpholine derivatives
AU2003243397A8 (en) Homo-camptothecin derivatives
GB0226609D0 (en) Heterocyclic derivatives
AP2005003311A0 (en) Substituted aralkyl derivatives
GB0311957D0 (en) Heterocyclic derivatives
AU2003285777A8 (en) 3-substituted-4-pyrimidone derivatives
GB0219894D0 (en) Dihydropyridinone derivatives

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)